PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS

Physiogenex provides preclinical in vivo and ex vivo CRO services with more than 15 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.

We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.

Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.

COVID-19 – While our priority is the health and safety of our staff, we operate thanks to an optimized organization and answer any request to run your research projects. Contact us

As international logistics and operation status of our providers are beyond our control, some unexpected delay could eventually occur depending on how the pandemic evolves overtime.
We are continuously monitoring the Covid-19 situation to keep our customers updated if needed.